Kiora Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	10.96	8.7	3.79	2.45	5.96	7.85
Short-Term Investments	2.92	8.39	23	-	-	-
Cash & Short-Term Investments	13.87	17.09	26.79	2.45	5.96	7.85
Cash Growth	-42.45%	-36.22%	991.47%	-58.85%	-24.06%	562.47%
Accounts Receivable	1.54	1.52	0.6	-	-	-
Other Receivables	1.91	1.79	0.27	2.05	1.37	0.53
Total Trade Receivables	3.45	3.32	0.87	2.05	1.37	0.53
Other Current Assets	1.36	1.34	2.04	0.23	0.34	0.61
Total Current Assets	18.68	21.75	29.71	4.74	7.68	8.99
Net Property, Plant & Equipment	0.39	0.38	0.06	0.11	0.17	0.28
Other Intangible Assets	2.06	2.06	6.69	8.81	10.74	10.77
Other Long-Term Assets	0.09	0.06	0.03	0.05	0.08	0.09
Total Assets	21.23	24.25	36.48	13.71	18.68	20.13
Accounts Payable	0.59	1.06	0.42	0.21	1.01	0.16
Accrued Expenses	2.03	2.41	4.59	1.38	1.84	1.33
Current Portion of Leases	0.18	0.16	0.02	0.05	0.11	0.12
Other Current Liabilities	-	-	0.98	-	0.32	-
Total Current Liabilities	2.8	3.63	6.01	1.63	3.27	1.61
Long-Term Leases	0.2	0.2	0.03	0.06	-	0.09
Other Long-Term Liabilities	4.3	4.29	4.68	5.91	4	3.85
Total Long-Term Liabilities	4.49	4.5	4.72	5.97	4	3.94
Total Liabilities	7.29	8.13	10.72	7.6	7.27	5.55
Preferred Stock	0	0	0	-	-	-
Common Stock	0.28	0.28	0.27	0.08	0.02	0
Additional Paid-in Capital	170.52	170.31	169.16	153.19	146.04	135.54
Accumulated Other Comprehensive Income	-0.23	-0.25	-0.28	-0.18	-0.18	-0.09
Retained Earnings	-156.64	-154.22	-143.38	-146.98	-134.46	-120.88
Shareholders' Equity	13.93	16.13	25.76	6.11	11.41	14.58
Total Liabilities & Equity	21.23	24.25	36.48	13.71	18.68	20.13
Total Debt	0.37	0.37	0.06	0.11	0.11	0.21
Net Cash (Debt)	13.5	16.72	26.73	2.35	5.86	7.65
Net Cash Growth	-43.63%	-37.46%	1038.72%	-59.93%	-23.37%	1150.70%
Net Cash Per Share	3.25	4.01	6.48	4.36	72.00	285.39
Book Value	13.93	16.13	25.76	6.11	11.41	14.58
Book Value Per Share	3.35	3.87	6.24	11.36	140.20	544.22
Tangible Book Value	11.87	14.06	19.07	-2.7	0.66	3.81
Tangible Book Value Per Share	2.86	3.38	4.62	-5.03	8.17	142.26

SEC Filings: 10-K · 10-Q